Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
24 Agosto 2023 - 9:30AM
Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan
Mikkelsen, President & Chief Executive Officer, and Scott
Smith, Executive Vice President & Chief Financial Officer, will
participate in three upcoming investor conferences.
Details:
Event |
Citi’s 18th Annual BioPharma Conference |
Location |
Boston, MA |
Date |
Thursday, September 7, 2023 |
Time |
2:40-3:25 p.m. Eastern Time / 11:40 a.m-12:25 p.m. Pacific
Time |
Event |
2023 Wells Fargo Healthcare Conference |
Location |
Boston, MA |
Date |
Friday, September 8, 2023 |
Time |
8:00-8:35 a.m. Eastern Time / 5:00-5:35 a.m. Pacific Time |
Event |
Morgan Stanley 21st Annual Global Healthcare Conference |
Location |
New York, NY |
Date |
Tuesday, September 12, 2023 |
Time |
12:55-1:25 p.m. Eastern Time / 9:55-10:25 a.m. Pacific Time |
A live webcast of the events will be available via the Investors
& News section of the Ascendis Pharma website at
investors.ascendispharma.com. A webcast replay will also be
available on this website shortly after conclusion of the event for
30 days.
About Ascendis Pharma A/SAscendis Pharma is
applying its innovative TransCon technology platform to build a
leading, fully integrated biopharma company focused on making a
meaningful difference in patients’ lives. Guided by its core values
of patients, science and passion, the company uses its TransCon
technologies to create new and potentially best-in-class therapies.
Ascendis is headquartered in Copenhagen, Denmark and has additional
facilities in Germany (Heidelberg, Berlin and Munich) and the
United States (Palo Alto and Redwood City, California, and
Princeton, New Jersey). Please visit ascendispharma.com to learn
more.
Forward-Looking Statements This press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statements of
historical facts, included in this press release regarding
Ascendis’ future operations, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to (i) Ascendis’
ability to apply its TransCon platform to build a leading, fully
integrated, global biopharma company, and (ii) Ascendis’ use of its
TransCon technologies to create new and potentially best-in-class
therapies. Ascendis may not actually achieve the plans, carry out
the intentions or meet the expectations or projections disclosed in
the forward-looking statements and you should not place undue
reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions,
expectations and projections disclosed in the forward-looking
statements. Various important factors could cause actual results or
events to differ materially from the forward-looking statements
that Ascendis makes, including the following: dependence on third
party manufacturers, distributors and service providers for
Ascendis’ products and product candidates; unforeseen safety or
efficacy results in Ascendis’ development programs or on-market
products; unforeseen expenses related to commercialization of any
approved Ascendis products; unforeseen expenses related to
Ascendis’ development programs; unforeseen selling, general and
administrative expenses, other research and development expenses
and Ascendis’ business generally; delays in the development of its
programs related to manufacturing, regulatory requirements, speed
of patient recruitment or other unforeseen delays; Ascendis’
ability to obtain additional funding, if needed, to support its
business activities; the impact of international economic,
political, legal, compliance, social and business factors,
including inflation, the effects on its business from the worldwide
COVID-19 pandemic and ongoing conflicts such as that in the region
surrounding Ukraine and Russia. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to Ascendis’ business in general, see Ascendis’
Annual Report on Form 20-F filed with the U.S. Securities and
Exchange Commission (SEC) on February 16, 2023 and Ascendis’ other
future reports filed with, or submitted to, the SEC.
Forward-looking statements do not reflect the potential impact of
any future licensing, collaborations, acquisitions, mergers,
dispositions, joint ventures, or investments that Ascendis may
enter into or make. Ascendis does not assume any obligation to
update any forward-looking statements, except as required by
law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company
logo and TransCon are trademarks owned by the Ascendis Pharma
group. © August 2023 Ascendis Pharma A/S.
|
|
|
Investor Contacts: |
|
Media Contact: |
Tim Lee |
|
Melinda Baker |
Ascendis Pharma |
|
Ascendis Pharma |
+1 (650) 374-6343 |
|
+1 (650) 709-8875 |
tle@ascendispharma.com |
|
media@ascendispharma.com |
ir@ascendispharma.com |
|
|
|
|
|
Patti Bank |
|
|
ICR Westwicke |
|
|
+1 (415) 513-1284 |
|
|
patti.bank@westwicke.com |
|
|
|
|
|
Ascendis Pharma AS (NASDAQ:ASND)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ascendis Pharma AS (NASDAQ:ASND)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024